鹭燕医药(002788) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 5,173,756,306.59, representing a 0.74% increase compared to CNY 5,135,680,997.86 in the same period last year[5] - Net profit attributable to shareholders decreased by 14.86% to CNY 71,323,645.12 from CNY 83,776,431.42 year-on-year[5] - Basic earnings per share fell by 18.18% to CNY 0.18 from CNY 0.22 in the same period last year[5] - Total operating revenue for the current period is approximately ¥5.17 billion, a slight increase from ¥5.14 billion in the previous period, representing a growth of about 0.3%[22] - Net profit for the current period is approximately ¥69.76 million, down from ¥83.52 million in the previous period, indicating a decrease of about 16.5%[23] - The company’s total comprehensive income for the current period is approximately ¥69.78 million, down from ¥83.53 million in the previous period, a decrease of about 16.5%[24] Cash Flow and Investments - The net cash flow from operating activities improved by 23.37%, reaching CNY -81,329,060.26 compared to CNY -106,133,464.90 in the previous year[5] - The net cash flow from investing activities improved by 54.21%, amounting to CNY -65,955,913.22 compared to CNY -144,025,906.71 in the previous year[10] - Cash flow from operating activities showed a net outflow of approximately ¥81.33 million, an improvement from a net outflow of ¥106.13 million in the previous period[25] - The company’s cash and cash equivalents at the end of the period stood at approximately ¥276.32 million, down from ¥308.54 million at the end of the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 12,628,639,470.41, a slight decrease of 0.08% from CNY 12,638,595,480.94 at the end of the previous year[5] - The company's current assets totaled CNY 9,833,468,783.15, compared to CNY 9,870,027,807.20 at the start of the period, indicating a decrease of approximately 0.37%[19] - The total liabilities of the company were CNY 9,366,337,106.38, down from CNY 9,446,689,554.59, representing a decrease of approximately 0.85%[20] - The company's total equity increased to CNY 3,262,302,364.03 from CNY 3,191,905,926.35, marking an increase of about 2.2%[21] - The company’s cash and cash equivalents decreased to CNY 457,879,572.29 from CNY 576,849,591.87, a decline of approximately 20.5%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,692[12] - The largest shareholder, Xiamen Meidiken Technology Co., Ltd., holds 35.53% of the shares, totaling 138,030,674 shares[12] Operational Metrics - The weighted average return on equity decreased to 2.23% from 2.80% year-on-year[5] - The company reported a significant reduction in receivables financing by 61.13%, down to CNY 15,110,744.01 from CNY 38,879,653.04[10] - The company’s inventory decreased to CNY 2,624,555,678.45 from CNY 2,864,755,977.45, a reduction of approximately 8.36%[18] - The company’s long-term borrowings stood at CNY 635,111,487.26, slightly down from CNY 648,408,776.05, indicating a decrease of about 2%[20] - The company's short-term borrowings increased to CNY 4,070,660,585.83 from CNY 3,874,674,322.37, reflecting an increase of about 5.5%[20] Research and Development - Research and development expenses increased to approximately ¥1.37 million from ¥1.22 million, marking a rise of about 12.9%[22] Legal Matters - The company has ongoing litigation to recover CNY 3,969.73 million from Guizhou Mingrun Construction Engineering Co., Ltd., with a court ruling awarding CNY 3,162.83 million[17] - The company received a total of CNY 78,005,000 from the bankruptcy asset distribution of Guizhou Dechangxiang Pharmaceutical Co., Ltd., with CNY 5,539,110.00 received by Huaron Yufu[15] Impairment and Losses - The company reported a decrease in investment income, with losses of approximately ¥5.06 million compared to losses of ¥3.55 million in the previous period[22] - The company experienced a decrease in credit impairment losses, which improved to approximately -¥8.76 million from -¥12.28 million in the previous period[23]